Research progress of pyruvate kinase type M2 in hepatocellular carcinoma.
10.3760/cma.j.cn501113-20200708-00379
- Author:
Dong Hui LU
1
;
Guo Ping SUN
2
;
Huan MA
1
;
Ming Jing XU
1
;
Shi Le GAO
1
;
Dong Mei WANG
1
Author Information
1. Department of Oncology, the 901st Hospital of the Joint Logistics Support Force of PLA, Hefei 230031, China.
2. Department of Oncology, the First Affiliated Hospital of Anhui Medical University, Hefei 230031, China.
- Publication Type:Journal Article
- Keywords:
Hepatocellular carcinoma;
Pyruvate kinase
- MeSH:
Carcinoma, Hepatocellular;
China;
Humans;
Liver Neoplasms;
Prognosis;
Pyruvate Kinase
- From:
Chinese Journal of Hepatology
2022;30(1):117-120
- CountryChina
- Language:Chinese
-
Abstract:
Primary hepatocellular carcinoma is one of the most common high-grade malignant tumors in the world. Its incidence ranks fifth among malignant tumors in China, and various therapeutic measures have poor curative effect. Pyruvate kinase type M2 is a key enzyme in the glycolytic pathway, and its abnormal expression in liver cancer is closely related to the proliferation, metastasis, diagnosis, treatment, prognosis, as well as drug and radiation resistance. Therefore, multi-pathway targeted regulation of pyruvate kinase type M2 use is expected to become a new direction for the treatment of primary liver cancer.
